.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
US Department of Justice
Chubb
Covington
McKinsey
Cantor Fitzgerald
Citi
Fish and Richardson
Merck

Generated: November 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,716,867

« Back to Dashboard

Which drugs does patent 6,716,867 protect, and when does it expire?


Patent 6,716,867 protects PRECEDEX and is included in one NDA. There have been zero Paragraph IV challenges on Precedex and Precedex

Protection for PRECEDEX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-five patent family members in twenty-seven countries.

Summary for Patent: 6,716,867

Title: Use of dexmedetomidine for ICU sedation
Abstract:The present invention relates to a method of sedating a patient while in the intensive care unit comprising administering dexmedetomidine of a pharmaceutically acceptable salt thereof to the patient, wherein the patient remains arousable and orientated.
Inventor(s): Aantaa; Riku (Turku, FI), Bachand; Romeo (Mundelain, IL), Heinonen; Esa (Turku, FI)
Assignee: Orion Corporation (Espoo, FI)
Application Number:09/647,364
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Hospira
PRECEDEX
dexmedetomidine hydrochloride
INJECTABLE;INJECTION021038-004Nov 14, 2014RXYesYes► Subscribe► SubscribeY
Hospira
PRECEDEX
dexmedetomidine hydrochloride
INJECTABLE;INJECTION021038-001Dec 17, 1999APRXYesYes► Subscribe► SubscribeY
Hospira
PRECEDEX
dexmedetomidine hydrochloride
INJECTABLE;INJECTION021038-002Mar 13, 2013RXYesYes► Subscribe► SubscribeY
Hospira
PRECEDEX
dexmedetomidine hydrochloride
INJECTABLE;INJECTION021038-003Mar 13, 2013RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,716,867

PCT Information
PCT FiledMarch 31, 1999PCT Application Number:PCT/FI99/00266
PCT Publication Date:October 07, 1999PCT Publication Number: WO99/49854

International Patent Family for Patent: 6,716,867

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovakia14362000► Subscribe
Slovenia1069893► Subscribe
Portugal1069893► Subscribe
Poland192517► Subscribe
Poland343553► Subscribe
New Zealand507203► Subscribe
Norway329194► Subscribe
Norway20004931► Subscribe
Japan4606581► Subscribe
Japan2002509880► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Chinese Patent Office
Accenture
US Army
Cantor Fitzgerald
Deloitte
Medtronic
Johnson and Johnson
Fish and Richardson
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot